Antisense oligonucleotides such as volanesorsen targeting apolipoprotein C-III was approved in 2019 in Europe for the treatment of familial chylomicronemia and the siRNA inclisiran in 2020 in Europe and in 2021 in the USA for the treatment of hypercholesterolemia. This evidence concerns the gene APOC3 and familial lipoprotein lipase deficiency.